Adrenogenic Autonomic Cortisol Secretion, Diagnosis, Treatment
Conditions
Keywords
Diagnosis and differential diagnosis, Treatment and prognosis, Adrenogenic Autonomic Cortisol Secretion
Brief summary
To investige the etiology, pathogenesis, diagnosis and treatment of adrenogenic autonomic cortisol secretion in Chinese adults.
Detailed description
With the development of imaging detection technology and its wide application in clinic, the detection rate of adrenal incidentaloma (AI) has been greatly improved. In our previous study, 18.9% of AI were accompanied by autonomic cortisol secretion (ACS) in Chinese. The vast majority of ACS is mild (MACS). Due to the lack of typical Cushing manifestations and the low rate of progression to overt Cushing, MACS has received insufficient attention in the past. However, recent studies have found that MACS have a higher incidence of diabetes, hypertension, cardiovascular events, metabolic bone disease and mortality risk than those with non-functional adenomas. With appropriate treatment, the complications of MACS patients can be effectively improved. However, personalized treatment of MACS is a clinical difficulty. It is hard to determine whether the cortisol secretion of patients is caused by AI or whether patients will benifit from operation. There are some retrospective studies have provided some evidence, while prospective studies are lacking. The purpose of this study is to prospectively include patients with autonomic cortisol secretion, evaluate function and diagnosis, develop personalized treatment strategy, and follow up the prognosis. The research results will provide new evidence for standardized diagnosis and treatment of adrenogenic autonomic cortisol secretion in the future.
Interventions
None listed
Sponsors
Chongqing Medical University
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* CT examination revealed adrenal nodules (maximum diameter ≥10mm); * Serum cortisol \> 50nmol/L after 1mg dexamethasone inhibition test (1mg-DST).
Exclusion criteria
* Patients with primary aldosteronism (PA), pheochromocytoma, adrenal metastatic carcinoma, congenital adrenal hyperplasia (CAH), ganglionic neuroma/paraganglioma, schwannoma, adrenal hematoma and those with no definite diagnosis were evaluated by clinical and endocrine function. * Patients with serious underlying diseases (such as liver and kidney failure, acute severe infection, etc.) that may affect the function of the hypothalamic-pituitary-adrenal axis (HPA axis); Pregnancy. * Patients with a history of alcoholism, fatigue, trauma, infection, depression, glucocorticoid use, and other drugs affecting the function of the hypothalamic-pituitary-adrenal axis. * Patients who are not willing to participate in and complete this study refuse to sign the written informed consent for this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SUVmax value of PET-CT | 10 years | To explore the value of 68\[Ga\]-Pentixafor PET-CT in the diagnosis of MACS |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Etiology and pathogenesis of adrenogenic autonomic cortisol secretion | 10 years | To study the etiology and pathogenesis of adrenogenic autonomic cortisol secretion |
Contacts
Primary ContactQifu Li, PhD
Backup ContactShumin Yang, PhD
Outcome results
None listed